A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease

A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in
Chronic Obstructive Pulmonary Disease

Inclusion Criteria:

- Age 45 through 75 years.

- Predicted (GOLD stage II, III, and IV) at screening.

- History of previous AECOPD 12 months prior to screening Clinically stable and free
from an AECOPD for 8 weeks prior to Day 1.

- Current smoker or ex-smoker with a tobacco history of ≥ 10 pack-years

Exclusion Criteria:

- Past or present disease or disorder,

- Significant or unstable ischemic heart disease, etc

- Known history of allergy or reaction to any component of the IMP

- Past or current malignancy within the past 5 years

- Subjects have had a chest x-ray or CT scan suggestive of malignancy or tuberculosis
(TB).

- Use of immunosuppressive medication receipt of any biologic agent